XERIS BIOPHARMA HOLDINGS, INC. (XERS) Operating income 2020–2025
XERIS BIOPHARMA HOLDINGS, INC. (XERS) annual operating income history from SEC filings — each fiscal year as reported.
$24.9MFY2025 · since FY2020: -$83.5M → $24.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $24.9M | +174.0% |
| FY2024 | -$33.6M | +23.5% |
| FY2023 | -$44.0M | +46.3% |
| FY2022 | -$81.9M | +28.8% |
| FY2021 | -$115.2M | -37.8% |
| FY2020 | -$83.5M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More XERS financial trends
XERS RevenueXERS Net incomeXERS Net marginXERS Gross profitXERS Gross marginXERS Operating marginXERS Operating cash flowXERS Free cash flowXERS Capital expendituresXERS Return on equityXERS Stock buybacksXERS Dividends paidXERS Total assetsXERS Total liabilitiesXERS Shareholders’ equityXERS overview →